Study objective: Low back pain causes more than 2.5 million visits to US emergency departments (EDs) annually. Low back pain patients are often treated with nonsteroidal anti-inflammatory drugs and benzodiazepines. The former is an evidence-based intervention, whereas the efficacy of the latter has not been established. We compare pain and functional outcomes 1 week and 3 months after ED discharge among patients randomized to a 1-week course of naproxenþdiazepam versus naproxenþplacebo.
INTRODUCTION Background
Low back pain is responsible for 2.4% of visits to US emergency departments (EDs), resulting in 2.7 million visits annually. 1 Pain outcomes for these patients are generally poor. 2 One week after an ED visit in an unselected low back pain population, 70% of patients report persistent back pain-related functional impairment and 69% report continued analgesic use. 2 Three months later, 48% reported functional impairment and 46% reported persistent analgesic use. Among the subset of ED patients who present with acute, new-onset low back pain, outcomes are generally better; most will recover, although more than 20% of this group will also report moderate or severe low back pain 3 months later and 30% will report low back pain-related functional impairment.
Editor's Capsule Summary
What is already known on this topic Benzodiazepines are often added to analgesic regimens for patients with acute lower back pain in the belief that sedation or relaxation will improve recovery.
What question this study addressed Does oral diazepam improve outcomes when added to naproxen in emergency department patients with acute nontraumatic and nonradicular low back pain?
What this study adds to our knowledge In a single-site, placebo-controlled, randomized trial with 114 subjects, diazepam did not improve 7-day or 3-month relief and did not alter adverse effects or subjective functioning.
How this is relevant to clinical practice
Diazepam should not be routinely added to nonsteroidal analgesics for these patients.
Importance
Nonsteroidal anti-inflammatory drugs are recommended as first-line therapy for patients with acute low back pain. 4 However, it is not clear whether the addition of other classes of therapeutic agents to nonsteroidal antiinflammatory drugs can further improve low back pain outcomes. Benzodiazepines are often mentioned as useful for these patients and are used in 300,000 US ED visits for low back pain annually, although scant evidence exists to determine the appropriateness of this approach. 5, 6 Efficacy of benzodiazepines, if any, may be related to direct or centrally mediated action on skeletal muscle or may work entirely or in part by mitigating patient anxiety about the condition. 7 
Goals of This Investigation
Because of the poor pain and functional outcomes that persist beyond an ED visit for musculoskeletal low back pain, we conducted a double-blind, randomized, clinical trial to evaluate whether combining a benzodiazepine with a nonsteroidal anti-inflammatory drug is more efficacious than nonsteroidal anti-inflammatory drug monotherapy for the treatment of acute, nontraumatic, nonradicular low back pain. Specifically, we wished to evaluate the following hypothesis: A daily regimen of naproxenþdiazepam would provide greater relief of functional impairment caused by low back pain than naproxenþplacebo, as measured by improvement in the Roland Morris Disability Questionnaire score 1 week after an ED visit.
MATERIALS AND METHODS Study Design and Setting
This was a randomized, double-blind, ED-based, comparative efficacy study conducted in 2 EDs of an urban health care system. We enrolled patients during an ED visit for acute musculoskeletal low back pain and followed them by telephone 7 days and 3 months later. Every patient received standard-of-care therapy, consisting of naproxen and a low back pain education session, in addition to either diazepam or placebo. The Albert Einstein College of Medicine Institutional Review Board reviewed and approved this study. We obtained written consent from all participants. Enrollment commenced in June 2015 and continued for 9 months.
We conducted this study in 2 EDs of Montefiore Medical Center, an urban teaching medical center, with 178,000 adult visits annually. Salaried, trained, fluently bilingual (English and Spanish) research associates staffed the EDs 24 hours per day, 7 days per week during the accrual period.
Selection of Participants
Our goal was to include a broad representation of patients with musculoskeletal back pain who were likely to respond to the investigational medications. We included adults aged 21 to 69 years who presented to the ED primarily for management of acute low back pain, defined as pain originating between the lower border of the scapulae and the upper gluteal folds. The primary clinical diagnosis at the conclusion of the ED visit was required to be one consistent with nontraumatic, nonradicular, musculoskeletal low back pain. We included only patients who were to be discharged home and those who had functionally impairing back pain, defined as a score of greater than 5 on the Roland-Morris Disability Questionnaire. The questionnaire is a validated 24-item tool commonly used to measure low back pain and related functional impairment, on which 0 represents no impairment and 24 represents maximum impairment (Appendix E1, available online at http://www. annemergmed.com).
We excluded patients from participation for radicular pain, defined as pain radiating below the gluteal folds in a dermatomal distribution, pain duration greater than 2 weeks (336 hours), or a baseline low back pain frequency of once per month or more frequently. We required the absence of nonmusculoskeletal cause of low back pain, such as urinary tract infection or influenzalike illness. Patients with direct trauma to the back within the previous month were excluded, as were those who were unavailable for follow-up; those who were pregnant or breast-feeding; those with a chronic pain syndrome, defined as use of any analgesic medication daily or almost daily; and those who were allergic to or intolerant of the investigational medications. We did not exclude patients for use of a nonsteroidal anti-inflammatory drug before ED presentation. Finally, patients could be enrolled only once.
Interventions
The pharmacist performed randomization in blocks of 4 according to a random-number sequence generated at http://randomization.com. Patients were randomized in a 1:1 manner to one of 2 interventions: the benzodiazepine arm (naproxen 500-mg tablets received twice per day plus diazepam 5 mg taken as 1 or 2 tablets every 12 hours) or the control arm (naproxen 500-mg tablets taken twice per day plus placebo received as 1 or 2 tablets every 12 hours).
In an effort to maximize effectiveness while minimizing adverse effects, we instructed patients to take 1 or 2 pills of the investigational medication every 12 hours. If one tablet of the investigational medication afforded sufficient relief, then there was no need for the patient to take the second tablet. However, if the patient had not experienced sufficient relief within 30 minutes of taking 1 investigational medication tablet, they were instructed to take the second tablet. We gave all study patients 20 naproxen tablets, a 10-day supply, and 28 tablets of the investigational medication, enough to last 7 days if the patient took the maximum dose of 2 tablets every 12 hours.
The pharmacists masked diazepam and placebo by placing tablets into identical capsules, which were packed with scant amounts of lactose and sealed. They performed the masking within the pharmacies, secure locations inaccessible to ED personnel. We then presented patients with 2 containers of medication. The container with the naproxen, labeled in a typical manner, was not masked. The second container, holding diazepam or placebo, was labeled as investigational medication.
Before discharge, research personnel delivered verbally to each participant a 10-minute educational intervention, based on the National Institute of Arthritis and Musculoskeletal and Skin Diseases's 5-page "What is back pain?" information sheet from the National Library of Medicine's Fun Facts: An Easy-to-Read Series of Publications for the Public (available at http://www. niams.nih.gov/Health_Info/Back_Pain/back_pain_ff.asp). We informed each participant that carefully chosen exercises and stretches may help pain and prevent future occurrences and that hot or cold packs, physical therapy, massage therapy, and acupuncture may help some patients.
Outcome Measures
The primary outcome for this study was improvement on the Roland Morris Disability Questionnaire between ED discharge and the 7-day telephone follow-up. A 5-point improvement on this scale is generally considered a clinically significant one. 8 Secondary outcomes 1 week and 3 months after ED discharge were as follows: 1 week after ED discharge, we determined (1) participants' worst pain during the previous 24 hours, using a 4-item ordinal scale (severe, moderate, mild, or none, dichotomized as severe/moderate versus mild/none for analysis); (2) the frequency of low back pain during the previous 24 hours, using a 5-item scale (not at all, rarely, sometimes, usually, and always, trichotomized as not at all/rarely versus sometimes versus usually/always for analysis); (3) the frequency of any analgesic or low back pain medication use during the previous 24 hours (dichotomized as use versus no use); (4) satisfaction with treatment, as measured by response to the question, "The next time you have back pain, do you want to take the same medications you've been taking this past week?"; (5) the number of days it took after ED discharge for the participant to return to usual activities; and (6) the frequency of visits to any clinician during the follow-up period. We determined how frequently participants used naproxen and the investigational medication by asking them to categorize their use of each as more than once per day, once per day, sometimes, only once, or never. Three months after ED discharge, we determined participants' absolute RolandMorris Disability Questionnaire score; their worst low back pain during the previous 72 hours, using the same ordinal scale as above; the frequency of low back pain during the previous 72 hours, using the same scale as above; and the frequency of use of any low back pain medication during the previous 72 hours, again dichotomized as use versus no use. Adverse events were ascertained by asking patients to report any symptoms from the medications. We specifically asked participants to describe whether the medications made them tired or dizzy or irritated their stomachs. For these latter 3 symptoms, participants were asked to use the descriptions "a lot," "a little," or "none." These measures have been used previously. 3 Research associates, who were blinded to study assignment, performed the follow-up telephone calls.
Primary Data Analysis
The primary analysis was intention to treat. All eligible participants with available outcome data were analyzed according to group assignment. The primary outcome was a comparison of the change in Roland-Morris Disability Questionnaire score between baseline and 1 week. These results are reported as means with 95% confidence interval (CI) and difference between the means of the 2 comparison groups with 95% CI. Dichotomous secondary outcomes are reported as proportions and difference between proportions with 95% CI.
We based our assumptions for the sample size calculation on a recently completed randomized controlled trial of low back pain treatment. 3 The mean improvement in Roland 
RESULTS

Characteristics of Study Subjects
During the study period, we approached 545 patients with low back pain for participation and randomized 114 eligible patients (Figure) . Baseline characteristics were comparable between the groups (Table 1 and Appendix E2 [available online at http://www.annemergmed.com]). The median initial Roland-Morris Disability Questionnaire score of 18 demonstrated substantial baseline functional impairment on presentation. Most patients had pain for no more than 2 or 3 days before presenting to the ED.
Main Results
One week after the ED visit, patients randomized to diazepam improved by a mean of 11 (95% CI 9 to 13) Roland-Morris Disability Questionnaire points, whereas placebo patients improved by 11 (95% CI 8 to 13) (95% CI for mean difference of 0.3: -2.8 to 3.5). The betweengroup difference achieved neither clinical nor statistical significance. Secondary outcomes were also comparable between the groups (Table 2 and Appendix E3 [available online at http://www.annemergmed.com]).
A majority of patients took naproxen at least once per day ( Table 3) . Use of the investigational medication (1) Before your back pain began, how often were you bothered by little pleasure or interest in doing things? (2) Before your back pain began, how often were you bothered by feeling down, depressed, or hopeless? Patients who responded to either question "More than half the days" or "Nearly every day" were considered to screen positive for depression. We discuss the presence or absence of spasm at baseline and discordance in work status in Appendix E2 (available online at http://www. annemergmed.com). (diazepam or placebo) among the study cohort was less common. Most of our patients did not visit another health care provider within 1 week of ED discharge (Table 3) .
Adverse events were relatively infrequent and comparable between the groups (Table 4) . Other than the symptoms reported in Table 4 , no more than 1 participant reported any other adverse event. There were no serious or unexpected adverse events.
By 3 months after the ED visit, most patients had recovered completely (Table 5 ). Similar to the findings at 1-week follow-up, differences in 3-month pain or functional outcomes between groups were neither clinically nor statistically significant.
LIMITATIONS
The first limitation is that in the interest of maintaining homogeneity for this study, we screened but did not include many patients because they did not meet our strict entry criteria. Thus, the study participants represent only a subset of patients who present to the ED with acute nontraumatic, nonradicular low back pain. These results therefore cannot be generalized to patients with other types of back pain, nor do they extend to those with chronic low back pain.
A second limitation is that we conducted this study in 1 urban health care system serving a socioeconomically depressed population. Because back pain outcomes may be associated with socioeconomic variables, our results can be generalized most appropriately to EDs that serve similar disadvantaged patient populations.
A third limitation is that we tested the combination of diazepam with naproxen, not diazepam alone. Thus, we do not know how diazepam would have fared by itself.
A fourth limitation is that we did not insist that patients receive these medications on a standing schedule but instead allowed them to receive the medications as needed. Therefore, it is possible that the true efficacy of diazepam was missed because of insufficient dosing. However, our study more closely mirrors the clinical reality of emergency practice.
Finally, we did not use presence or absence of muscle spasm on clinical examination as an entry criterion because the clinical significance of this finding is uncertain. 9 Furthermore, it cannot be assessed pragmatically in a reliable and accurate manner. It is plausible that patients with true muscular spasm would have fared better with the active medication.
DISCUSSION
Diazepam is currently used in approximately 300,000 visits for low back pain to US EDs annually. 1 Given its frequent usage, there is a surprising paucity of evidence in regard to its efficacy. We identified 4 studies in which diazepam was compared with placebo for low back pain and 1 in which it was compared with aspirin. Brotz et al 10 prescribed physiotherapy and diclofenac to 60 patients hospitalized with lumbar disc prolapse and then randomized the patients into placebo and diazepam study arms. When compared with the diazepam group, the placebo group was found to have a shorter hospital stay and a higher probability of greater than 50% reduction in pain by day 7. However, there were no differences *At the 7-day follow-up, we asked study participants specifically whether they experienced dizziness, feeling tired, and stomach irritation. They were asked to choose among the following options: "no," "a little," and "a lot."
in functional outcome. Hingorani 5 randomized 50 hospitalized patients with various causes of acute low back pain to diazepam or placebo and found no difference in subjective or objective outcomes. Brown and Womble 11 randomized 49 patients with chronic back or neck pain to diazepam, cyclobenzaprine, or placebo groups and used a global outcome measure that encompassed change in level of pain, spasm, mobility, tenderness to palpation, and restriction in activities. The cyclobenzaprine patients had better outcomes than the diazepam patients, who had better outcomes than patients randomized to placebo. Basmajian 12 randomized 105 patients with neck or back pain to diazepam, cyclobenzaprine, and placebo and found no statistically significant differences among the groups.
Our data contribute to an increasing body of literature suggesting that, in general, most medications do not improve acute low back pain. We demonstrated previously that adding cyclobenzaprine or oxycodone/acetaminophen to naproxen is unlikely to benefit patients with new-onset nonradicular low back pain. 3 Similarly, patients with nonradicular low back pain appear to receive no benefit from either corticosteroids 13 or acetaminophen.
14 Complementary therapies, including acupuncture, 15 yoga, 16 and massage 17 may be offered but have been inadequately studied to assess efficacy in an acute low back pain population. Spinal manipulation is unlikely to benefit ED patients with acute low back pain who are well managed medically. 18 Physical therapy may be useful for some patients. 19 Emergency physicians should counsel their patients that passage of time will bring improvement and eventual relief to most of them. Overall, 1-week and 3-month outcomes in this study were generally better than in other ED-based work. 2, 3, 13, 20 This is partly explained by our selection criteria, which excluded patients with chronic or frequent episodic low back pain, who have been shown to have worse outcomes. 21 However, in all ED-based studies, 25% to 40% of patients with acute, new-onset low back pain report moderate or severe low back pain 1 week after ED discharge, and 10% to 25% of these patients report moderate or severe pain 3 months later. Ideally, patients at higher risk of poor outcome should be targeted for close follow-up, with the goal of preventing the transition from acute to chronic pain. Unfortunately, it is difficult to predict which patients with acute low back pain are at risk of poor outcomes.
Enrollment in this study did not commence until an individual was ready for discharge from the ED. Therefore, we do not know whether diazepam has a role in the acute management of acute low back pain, ie, whether it can increase the likelihood of discharge among patients who arrive in the ED with marked functional impairment because of low back pain of sufficient severity that hospitalization may be necessary. Also, we excluded from participation patients with chronic or frequent episodic low back pain. A systematic review suggests that these patients are at increased risk of poor outcomes if they are prescribed benzodiazepines. 4 In conclusion, diazepam does not appear to confer any benefit beyond that of placebo when added to naproxen for the treatment of nonradicular, nontraumatic, acute low back pain. Author contributions: BWF, CS, and EJG conceived the study and designed the trial. BWF, EI, CS, and EZ supervised the conduct of the trial and data collection. BWF, EI, and JZ managed the data, including quality control. BWF analyzed the data. BWF and NK drafted the article, and all authors contributed substantially to its revision. BWF takes responsibility for the paper as a whole.
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